| Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
We have developed orthotopic patient-derived xenograft models of HER2 positive breast cancer metastasized into the brain of patients to test novel therapeutic strategies. In this study, we identified a novel combinatorial therapeutic strategy that has resulted in a durable remission and markedly increased overall survival in majority of patient-derived xenograft (PDX) models tested. We performed whole exome sequencing analysis of these PDX tumors and their matched blood and patient samples to investigate drug sensitive and resistance mechanisms. Our sequencing data revealed an interesting association of genotyping and phenotyping with tumors responses to drug treatment.
- Study Design:
- Case Set
- Study Type:
- Case Set
- Total number of consented subjects: 12
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
- Study Inclusion/Exclusion Criteria
Her2+ breast cancers that metastasized to the brain
- Molecular Data
-
Type Source Platform Number of Oligos/SNPs SNP Batch Id Comment Whole Exome Sequencing Thermo Fisher Scientific Ion Proton N/A N/A fastq file format - Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
- Links to Related Genes
- Authorized Data Access Requests
-
See articles in PMC citing this study accession
- Study Attribution
-
-
Principal Investigator
- Jean J. Zhao, PhD. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
-
Co-Principal Investigators
- Keith L. Ligon, MD, PhD. Dana-Farber Cancer Institute, Boston Children's Hospital, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Nancy U. Lin, MD. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
- Eric P. Winer, MD. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
-
Co-Investigators
- Jing Ni, PhD. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
- Shakti H. Ramkissoon, MD, PhD. Dana-Farber Cancer Institute, Boston Children's Hospital, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Shaozhen Xie, PhD. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
- Daniel G. Stover, MD, PhD. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
- Shom Goel, MD, PhD. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
- Lori A. Ramkissoon, PhD. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
-
Other Investigator
- Thomas M. Roberts. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
-
Principal Investigator